Abstract
1,3-Dipolar cycloaddition of nonstabilized azomethine ylides derived from α-C-H functionalization of tetrahydroisoquinoline for regio- and diastereoselective synthesis of spirooxindole-pyrrolidines is developed. A three-component reaction of readily available cyclic amine, aryl aldehydes, and olefinic oxindoles provides a pot, atom and step economy (PASE) approach for making spiro-heterocyclic compounds with biological interest
Graphical Abstract

Acid additive-promoted regio- and diastereoselective 1,3-dipolar cycloaddition of nonstabilized azomethine ylides with olefinic oxindoles afforded biologically interested spirooxindole-pyrrolidines
Introduction
There are numbers of biologically active natural and synthetic compounds bearing the spirooxindole moiety,1,2 such as drugs molecules (+)-alstonisine,3 pteropodine,4 spirotryprostatin A,5 and (+)-limaspermidine (Fig. 1).6 Spirooxindole compounds have also been developed as MDM2 inhibitors for the treatment of cancer diseases (Fig. 2).7 Among them, the spirooxindole-pyrrolidine compounds C and D were prepared through a two-step synthesis involving 1,3-dipolar [3+2] cycloaddition of stabilized azomethine ylides with olefinic oxindoles.8,9
Fig. 1.
Bioactive spirooxindole-pyrrolidine derivatives
Fig. 2.
Spirooxindole MDM2 inhibitors and synthesis
α-Amino ester or α-amino acid-based [3+2] cycloadditions of stabilized azomethine ylides10–13 with olefinic oxindoles, including organocatalyzed asymmetric synthesis, for making spirooxindole-pyrrolidines have been well documented (Scheme 1A).14,15 Also reported are cycloadditions of piperidine-2-carboxylates (Scheme 1B)16 and cycloadditions involving both isotins and olefinic oxindoles (Scheme 1C).17 α-Amino acid-based decarboxylative [3+2] cycloaddition of non-stabilized azomethine ylides18,19 for spirooxindole derivatives has also been developed (Scheme 1D).20
Scheme 1.
Olefinic oxindole-based 1,3-dipolar cycloadditions for spirooxindole-pyrrolidine
Since cyclic amines could be used to replace α-amino esters or α-amino acids to form ylides through H-transfer at α-C-H of the amines for cycloadditions,21,22 we envisioned that a new method could be developed for diastereoselective synthesis of spirooxindole-pyrrolidine compounds 1 structurally related to MDM2 inhibitor D (Scheme 1E). It is a [3+2] cycloaddition of olefinic oxindoles with nonstabilized azomethine ylides derived from cyclic amines. The product ring skeleton (in blue colour) and the positions of R and R3 in 1 and the product in Scheme 1B are different. The later one is produced from the cycloaddition of olefinic oxindoles with stabilized ylides derived from piperidine-2-carboxylates.16 In addition to form different product structure, the new method is a one-pot and three-component reaction with high pot, atom, and step economy (PASE).23,24
Results and discussion
The development of reaction conditions for the one-pot 1,3-dipolar cycloaddition of non-stabilized azomethine ylides was carried out using 1,2,3,4-tetrahydroisoquinoline (THIQ) 2a, 4-bromobenzaldehyde 3a, and olefinic oxindole 4a as substrates (Table 1). After screening reaction conditions using different Brønsted acid catalysts such as BzOH, AcOH, TFA, K10, and Zeolite YH (entries 1–10), it was found that a reaction of 1.3:1.1:1.0 of 2a:3a:4a with 0.5 equiv of BzOH in EtOH under microwave at 125 °C for 30 min afforded 67% isolated yield of spirooxindole-pyrrolidine 1a with 6:1 dr (entry 5). Reactions with a solid Brønsted acid catalysts such as K10 or Zeolite YH gave product up to 69% LC yield and 4:1 dr (entries 9 and 10). Using MeCN, toluene, or dioxane as a solvent didn’t give better than 77% LC yield (entries 11–13).
Table 1.
Conditions for the one-pot reaction
| ||||||
|---|---|---|---|---|---|---|
| entry | solvent | cat. (0.5 equiv) | T (°C) | t (min) | 1a (%)b | dr |
| 1 | EtOH | -- | 90 | 45 | 55 | 3:1 |
| 2 | EtOH | BzOH | 90 | 45 | 61 | 4:1 |
| 3 | EtOH | BzOH | 150 | 45 | 71 | 6:1 |
| 4 | EtOH | BzOH | 125 | 45 | 75 | 6:1 |
| 5 | EtOH | BzOH | 125 | 30 | 77 (63%) | 6:1 |
| 6 | EtOH | BzOH | 125 | 15 | 68 | 5:1 |
| 7 | EtOH | AcOH | 125 | 30 | 70 | 6:1 |
| 8 | EtOH | TFA | 125 | 30 | 43 | 4:1 |
| 9 | EtOH | K10 | 125 | 30 | 63 | 4:1 |
| 10 | EtOH | Zeolite YH | 125 | 30 | 69 | 2.5:1 |
| 11 | MeCN | BzOH | 125 | 30 | 75 | 4.5:1 |
| 12 | toluene | BzOH | 125 | 30 | 46 | 4:1 |
| 13 | dioxane | BzOH | 125 | 30 | 67 | 6:1 |
Microwave heating, dr determined by 1H-NMR.
LC yield, isolated yield in parenthesis.
Under the optimized conditions, the scope of the one-pot synthesis was evaluated in the preparation of spirooxindole-pyrrolidines 1 which are structurally related to MDM2 inhibitor D (Table 2). Reactions of different aldehydes 3 and olefinic oxindoles 4 with gave products 1a–k in 39–77% yields and up to 7:1 dr. The results indicate that substituents on benzene of aromatic aldehydes affects the product yield such as 1e (2-F-5-BrC6H3, 39% yield). Olefinic oxindoles 4 with different R1, R2 and R3 were conferred for the construction of 1f–k. Most products have an ester group (−CO2Et) as R3. In the case of ketone (R3 = −COMe), product 1j was formed in 55% yield. However, product 1l (R3 = Ph) was obtained in a trace amount, which was also observed in previously reported [3+2] cycloaddition reactions.20 Reactions of heterocyclic aldehydes gave 1k (furanyl) in 68% yield, but 1m (pyridyl) in a trace amount due to its basicity offsets the Brønsted acid catalyst. Reactions of aliphatic aldehydes resulted products 1n–p as complex diastereomeric mixtures due to aldehydes’ low reactivity and diastereoselectivity.19b,19e Further extension of the reaction scope by using tetrahydronorharman (THBC) or isoindoline as cyclic amines gave 5a and 6a in 79% and 46% yield, respectively (Scheme 2). The [3+2] cycloaddition adducts generated from 2-azidobenzaldehyde and 2-nitrobenzaldehyde were derivatized by reducing the −NO2 and −N3 groups to −NH2 for lactamization to give highly condensed-polycyclic spirooxindole 7a in 32% and 51% yield, respectively (Scheme 3).
Table 2.
Synthesis of substituted spirooxindole-pyrrolidines 1
|
Isolated yield. Reaction conditions are same as Table 1, entry 5.
Scheme 2.
Reactions using THBC or isoindoline as cyclic amine
Scheme 3.
One-pot synthesis of polycyclic compound 7a
The stereochemistry of the [3+2] cycloaddition products was established by X-ray crystal structure analysis of a representative compound 1a (Fig. 3). On the basis of product structure and stereochemistry, a mechanism for the diastereoselective [3+2] of azomethine ylides with THIQ is proposed in Scheme 4. The condensation of THIQ with an aldehyde leads to the formation of an iminium ion and then an azomethine ylide in form I or II. As it has been reported that carboxylic acid facilitates amine α-functionalization for azomethine ylides cycloaddition.22a Acid additives could alter the regioselectivity of 1,3-dipolar cycloaddition.25 In this work, addition of BzOH promote the cycloaddition of ylide I with an olefinic oxindole to give spirooxindole-pyrrolidines 1 as a major diastereomer. Cycloaddition of azomethine ylide II for product 1” does not happen. However, this pathway is favourable for the reaction shown in Scheme 1B, which is a cycloaddition of an olefinic oxindole with a stabilized azomethine ylide derivatized from piperidine-2-carboxylate.16 Those results indicate that the [3+2] cycloadditions of stabilized or non-stabilized ylides have different regioselectivity.
Fig. 3.
X-ray structure of compound 1a
Scheme 4.
Mechanism for cycloaddition of non-stabilized ylides derived from THIQ
Conclusions
In summary, a three-component [3+2] cycloaddition involving cyclic amines such as THIQ, THBC and isoindoline has been developed for diastereoselective synthesis of pyrrolidine-based spiro-polycyclic compounds. Some of the product structures are closely related to reported MDM2 inhibitors. The new method has advantages of high synthetic efficiency, operation simplicity, and only stoichiometric amount water and CO2 were produced as side-products. The biological test results of the newly synthesized compounds will be reported in due course.
Supplementary Material
Acknowledgement
This work was partly supported by the NIH grant T32 CA 236754–1 (X.Z). We thank Jason Evans and Dennis Zeh for performing the HRMS analysis of compounds.
Footnotes
Conflicts of interest
There are no conflicts to declare.
Electronic Supplementary Information (ESI) available: Detailed experimental procedures, compound characterization, NMR spectra, green chemistry metrics analysis. See DOI: 10.1039/x0xx00000x
Notes and references
- 1.For selected reviews, see: Ye N, Chen H, Wold EA, Shi PY, and Zhou J, ACS Infect Dis, 2016, 2, 382–392;Beloglazkina A, Zyk N, Majouga A and Beloglazkina E, Molecules, 2020, 25, 1211;Yu B, Yu Z, Qi P, Yu DQ and Liu HM, Eur. J. Med. Chem, 2015, 95,35–40;Zhou L, Qu R and Yang G, Expert Opin. Drug Dis, 2020, 15, 603–625;Sanz G, Singh M, Peuget S, Selivanova G, J. Mol. Cell Bio, 2019, 11, 586–599.
- 2.For selected research papers, see: Wang B, Peng F, Huang W, Zhou J, Zhang N, Sheng J, Haruehanroengra P, He G and Han B, Acta Pharmaceutica Sinica B, 2020, 10, 1492–1510;Ren W, Zhao Q, Yu M, Guo L, Chang H, Jiang X, Luo Y, Huang W and He G, Mol. Divers, 2020, 24,1043–1063;Shi X, Yu B, Wang JW, Qi P, Tang K, Huang X and Liu H, Sci. Rep-UK, 2016, 6, 31607;Barakat A, Islam MS, Ghawas HM, Al-Majid AM, El-Senduny FF, Badria FA, Elshaiere YAMM and Ghabbour HA, RSC Adv, 2018, 8, 14335–14346.
- 3.Yang J, Wearing XZ, Quesne PW, Deschamps JR and Cook JM, J. Nat. Prod, 2008, 71, 1431–1440. [DOI] [PubMed] [Google Scholar]
- 4.Martin SF and Mortimore M, Tetrahedron Lett, 1990, 31, 4557–4560. [Google Scholar]
- 5.Onishi T, Sebahar PR, and Williams RM, Org. Lett, 2003, 5, 3135–3137. [DOI] [PubMed] [Google Scholar]
- 6.White KL and Movassaghi M, J. Am. Chem. Soc, 2016, 138, 35, 11383–11389. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ding Q, Liu J-J and Zhang Z, WO Patent WO 2007/104714, 2007.
- 8.Aguilar A, Sun W, Liu L, Lu J, McEachern D, Bernard D, Deschamps JR and Wang S, J. Med. Chem, 2014, 57, 10486–10498. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Wang S, Ding K, Lu Y, Nikolouska-Coleska Z, Qiu S, Qin D and Shangary S, WO Patent WO 2006/091646 A2, 2006.
- 10.Zhang W, Chem. Lett, 2013, 46, 676–681. [Google Scholar]
- 11.Selected reviews on 1,3-dipolar cycloadditions, see: Tang S, Zhang X, Sun J, Niu D and Chruma J, Chem. Rev, 2018, 118, 10393–10457;Coldham I and Hufton R, Chem. Rev, 2005, 105, 2765–2810;Pandey G, Banerjee P and Gadre SR, Chem. Rev, 2006, 106, 4484–4517;Gothelf KV and Jorgensen KA, Chem. Rev, 1998, 98, 863–910;Narayan R, Potowski M, Jia ZJ, Antonchick AP and Waldmann H, Acc. Chem. Res, 2014, 47, 1296–1310;Martina K, Tagliapietra S, Veselov VV and Cravotto G, Front. Chem, 2019, 7, 95.
- 12.Selected examples of amino ester-based 1,3-dipolar cycloadditions, see: Cheng D, Ishihara Y, Tan B and Barbas CF, ACS Catal, 2014, 4, 743–762;Ball-Jones NR, Badillo JJ and Franz AK, Org. Biomol. Chem, 2012, 10, 5165–5181;Fang X and Wang CJ, Org. Biomol. Chem, 2018, 16, 2591–2601;Zhang JX, Wang HY, Jin QW, Zheng CW, Zhao G and Shang YJ, Org. Lett, 2016, 18, 4774–4777.Yildirim O, Grigalunas M, Brieger L, Strohmann C, Antonchick AP, and Waldmann H, Angew. Chem., Int. Ed, 2021, 60, 20012–20020;Motornov VA, Tabolin AA, Nelyubina YV, Nenajdenko VG and Ioffe SL, Org. Biomol. Chem, 2021, 19, 3413–3427.
- 13.Our recent works on amino ester-based 1,3-dipolar cycloadditions, see: Lu Q, Song G, Jasinski JP, Keeley AC and Zhang W, Green Chem, 2012, 14, 3010–3012;Zhang W, Lu YM and Geib S, Org. lett, 2005, 7, 2269–2272;Zhang XF, Qiu WQ, Ma XM, Evans J, Kaur M, Jasinski JP and Zhang W, J. Org. Chem, 2018, 83, 13536–13542;Zhang XF, Zhi S, Wang W, Liu S, Jasinski JP, Zhang W, Green Chem, 2016, 18, 2642–2646;Zhang XF, Pham K, Liu S, Legris M, Muthengi A, Jasinski JP and Zhang W, Beilstein J. Org. Chem, 2016, 12, 2204–2210.
- 14.For selected reviews on organocatalyzed [3+2] cycloadditions, see: Rios R, Chem. Soc. Rev, 2012, 41, 1060–1074;Wang Y, Cobo AA and Franz AK, Org. Chem. Front, 2021, 8, 4315–4348.
- 15.For selected papers organocatalyzed [3+2] cycloadditions, see: Zhang J-X, Wang H-Y, Jin Q-W, Zheng C-W, Zhao G and Shang Y-J, Org. Lett, 2016, 18, 4774–4777;Chen X, Wei Q, Luo S, Xiao H and Gong L, J. Am. Chem. Soc, 2009, 131, 13819–13825;Cui H, Li K, Wang Y, Song M, Wang C, Wei D, Li E, Duan Z and Mathey F, Org. Biomol. Chem, 2020, 18, 3740–3746.
- 16.Jatoi WB, Pugetb P, Jatoia AH and Shara GQ, Pharm. Chem. J, 2014, 48, 288–291. [Google Scholar]
- 17.(a) Almansour AI, Arumugam N, Kumar RS, Periyasami G, Ghabbour HA and Fun HK, Molecules, 2015, 20, 780–791; [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Qian YL, Li B, Xia PJ, Wang J, Xiang HY and Yang H, Tetrahedron, 2018, 74, 6821–6828; [Google Scholar]; (c) Xu Q, Wang D, Wei Y, Shi M, ChemistryOpen, 2014, 3, 93–98; [DOI] [PMC free article] [PubMed] [Google Scholar]; (d) Xiao J-A, Zhang H-G, Liang S, Ren J-W, Yang H and Chen X-Q, J. Org. Chem, 2013, 78, 11577–11583. [DOI] [PubMed] [Google Scholar]
- 18.For selected examples of amino acid-based 1,3-dipolar cycloadditions, see: Coldham I, Burrell AJM, White LE, Adams H and Oram N, Angew. Chem. Int. Ed, 2007, 46, 6159–6162;Saraswat P, Jeyabalan G, Hassan MZ, Rahman MU and Nyola NK, Synth. Commun, 2016, 46, 1643–1664;Rehn S, Bergman J and Stensland B, Eur. J. Org. Chem, 2004, 413–418;Boudriga S, Haddad S, Murugaiyah V, Askri M, Knorr M, Strohmann C and Golz C, Molecules, 2020, 25, 1963.
- 19.For our recent works in the amino acid-based 1,3-dipolar cycloadditions, see: Zhang XF, Liu M, Zhang WS, Legris M and Zhang W, J. Fluorine Chem,2017, 204, 18–22;Zhang XF, Qiu WQ, Evans J, Kaur M, Jasinski JP and Zhang W, Org. Lett, 2019, 21, 2176–2179;Ma XM, Zhang XF, Qiu WQ, Zhang W, Wan B, Evans J and Zhang W, Molecules, 2019, 24, 601–607;Ma XM, Meng SZ, Zhang XF, Zhang Q, Yan SH, Zhang Y and Zhang W, Beilstein J. Org. Chem, 2020, 16, 1225–1233;Ma XM, Qiu W, Liu L, Zhang XF, Award J, Evans J and Zhang W, Green Synth. Catal, 2021, 2, 74–77.
- 20.Zhang XF, Qiu Q, Murray SA, Zhan D, Kaur M, Jasinski JP and Zhang W, J. Org. Chem, 2021, 86, 17395–17403. [DOI] [PubMed] [Google Scholar]
- 21.(a) Seidel D, Acc. Chem. Res, 2015, 48, 317–328; [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Min C and Seidel D, Chem Soc. Rev. 2017, 46, 5889—5902. [DOI] [PubMed] [Google Scholar]
- 22.(a) Mantelingu K, Lin YF and Seidel D, Org. Lett, 2014, 16, 5910–5913; [DOI] [PMC free article] [PubMed] [Google Scholar]; (b) Ma L, Paul A, Breugst M and Seidel D, Chem. Eur. J, 2016, 22, 18179–18189; [DOI] [PMC free article] [PubMed] [Google Scholar]; (c) Zhang XF, Liu M, Qiu Q, Evans J, Kaur M, Jasinski JP and Zhang W, ACS Sustainable Chem. Eng, 2018, 6, 5574–5579. [Google Scholar]
- 23.For a book and selected reviews on PASE, see: Yi WB and Zhang W, Pot, Atom, and Step Economy (PASE) Synthesis, Springer, Cham, 2019;Hayashi Y, Chem. Sci, 2016, 7, 866–880;Sydnes MO, Curr. Green Chem, 2014, 1, 216–226;Clarke PA, Santos S and Martin WHC, Green Chem, 2007, 9, 438–440;Zhang X and Zhang W, Curr. Opin. Green Sustain. Chem, 2018, 11, 65–69.
- 24.(a) Huang X, Pham K, Yi W, Zhang XF, Clamens C, Hyatt JH, Jasinsk JP, Tayvah U and Zhang W, Adv. Synth. Catal, 2015, 357, 3820–3824; [Google Scholar]; (b) Bhuyan D, Sarma R, Dommaraj Y and Prajapati D, Green Chem, 2014, 16, 1158–1162; [Google Scholar]; (c) Zhang XF, Ma XM, Qiu WQ, Evans J and Zhang W, Green Chem, 2019, 21, 349–354; [Google Scholar]; (d) Zhang XF, Ma XM, Qiu WQ, Award J, Evans J and Zhang W, Adv. Synth. Catal, 2020, 362, 5513–5517. [Google Scholar]
- 25.(a) Galvis CEP and Kouznetsov VV, Org. Biomol. Chem, 2013, 11, 7372–7386; [DOI] [PubMed] [Google Scholar]; (b) Peng C, Ren J, Xiao J-A, Zhang H, Yang H and Luo Y, Beilstein J. Org. Chem, 2014, 10, 352–360. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.







